Liprolog (Insulin Lispro)

Insulin lispro mimics natural insulin by binding to insulin receptors on muscle, fat and liver cells. This activates intracellular pathways that increase glucose uptake into cells and suppress liver glucose production, resulting in a rapid decline in blood glucose levels after meals.

The dose of Liprolog is individualized. A prescriber determines the amount and timing based on the patient’s blood glucose patterns, carbohydrate intake, and overall treatment plan. Patients should follow the dosing instructions provided by their healthcare professional.

The safety of insulin lispro in pregnancy and lactation has not been fully established. It may be used if the potential benefit to the mother outweighs any potential risk to the fetus or infant. Decisions should be made in consultation with a qualified obstetric or pediatric specialist.

To order Liprolog, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

Liprolog (insulin lispro) shares the rapid onset and short duration profile of other rapid‑acting analogs such as insulin aspart and insulin glulisine. Clinical differences are minimal; choice often depends on formulary availability, patient preference, and specific pharmacokinetic nuances observed in individual response.

Liprolog should be stored at 2‑8 °C (refrigerated) in its original carton, protected from light. Do not freeze or shake the vial. Once in use, the product may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, after which any remaining solution should be discarded.

Liprolog is supplied as a clear solution for injection and can be given subcutaneously or intravenously. Subcutaneous injection is typically performed in the abdomen, thigh, or upper arm using a short‑acting needle. Intravenous administration is reserved for hospital settings, such as during surgery or acute glucose control.

The most serious risks include severe hypoglycemia, which can lead to loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated on recognizing early signs of hypoglycemia and instructed to seek immediate medical attention if a severe reaction occurs.

Liprolog is contraindicated in individuals with a known hypersensitivity to insulin lispro or any of the excipients in the formulation. It should also be avoided in patients with severe hypoglycemia unawareness unless closely monitored, and in those for whom rapid‑acting insulin is not appropriate as determined by a qualified healthcare provider.